Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Queen

Internal Medicine Sylva, NC Medical Doctor

NPI 1760440812 CMS profile 351658

98 Doctors Dr, Suite 200, Sylva, NC 28779

Open in the dashboard

General payments

$11,165

602 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steven Queen of Sylva, NC is reported in the CMS Open Payments database as having received $11,165 across 602 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,160 46
2024 General $1,231 42
2023 General $2,073 103
2022 General $2,380 138
2021 General $1,504 83
2020 General $625 33
2019 General $2,193 157

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Queen
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Steven Queen were reported at $1,160. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Steven Queen Internal Medicine median Middle half National median
2019 $2,193 $159 $48–$570 $163
2020 $625 $119 $33–$402 $114
2021 $1,504 $135 $37–$521 $132
2022 $2,380 $141 $42–$496 $149
2023 $2,073 $149 $45–$519 $160
2024 $1,231 $154 $47–$537 $164
2025 $1,160 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,608 82 payments
  2. Novo Nordisk Inc $1,283 70 payments
  3. AstraZeneca Pharmaceuticals LP $1,039 46 payments
  4. Amgen Inc. $882 50 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $785 47 payments
  6. GlaxoSmithKline, LLC. $616 35 payments
  7. Lilly USA, LLC $571 35 payments
  8. Pfizer Inc. $554 34 payments
  9. Janssen Pharmaceuticals, Inc $510 19 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $475 30 payments
  11. Other $2,840 154 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,129 596 payments
  2. Education $36 6 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR $978 39 payments
  2. Ozempic $832 45 payments
  3. XIFAXAN $785 47 payments
  4. RYBELSUS $563 32 payments
  5. TRELEGY ELLIPTA $495 32 payments
  6. Repatha $426 28 payments
  7. XARELTO $399 15 payments
  8. FARXIGA $360 21 payments
  9. UBRELVY $308 19 payments
  10. Otezla $306 15 payments
  11. Other $9,272 543 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 193 drugs

Part D claims

12,924

Median for Internal Medicine: 777

Drug cost

$1,181,785

Median for Internal Medicine: $73,373

Branded share of claims

19.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 159 $135,784
Jardiance Empagliflozin Brand 95 $125,827
Xarelto Rivaroxaban Brand 87 $83,044
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 78 $81,393
Otezla Apremilast Brand 15 $72,734
Mounjaro Tirzepatide Brand 40 $56,051
Entresto Sacubitril/Valsartan Brand 51 $53,176
Repatha Sureclick Evolocumab Brand 54 $43,531
Myrbetriq Mirabegron Brand 45 $34,555
Kerendia Finerenone Brand 23 $32,765

The 10 drugs with the highest cost, of 193 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$66,073

Medicare's payments for the services billed

Medicare patients

317

Average age 76

Services billed

965

172 women, 145 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 43%
Diabetes 23%
Ischemic heart disease 19%
Atrial fibrillation 16%
Depression 16%
Osteoporosis 16%
COPD 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $149
$149 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $137
$137 — —
Otezla
  • Amgen Inc. $104
$104 15 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $85
$85 95 —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $65
$65 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

602 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record